Ultra Wellness Utah

Tirzepatide research education entry

Dual GLP-1/GIP receptor agonist studied in SURMOUNT and SURPASS Phase 3 clinical trials for metabolic support.

About this page

Tirzepatide is a dual GIP/GLP-1 receptor agonist that has shown mean weight reductions of up to 20.9% in Phase 3 SURMOUNT trials. It is one of the most studied metabolic peptides available, with robust clinical data supporting its effects on body weight, insulin sensitivity, and cardiovascular risk markers.

Category: Weight Management & Metabolic Health. View the linked research sources and related educational resources for additional context.